Danish biotechnology company Bavarian Nordic has been awarded a joint procurement contract by the European Commission, according to a press release.
The contract enables the EU, its member states, and additional European countries to purchase up to eight million doses of the company's vaccine against smallpox/mpox.
The agreement is valid for two years and can be extended for an additional two years. It builds upon a previous contract from 2022, which aimed to ensure a continuous supply of the vaccine throughout Europe.
"With the signing of the agreement, approximately 1.1 million doses have already been contracted, with delivery of the first 750,000 doses expected in 2026," the company stated.
